Here is the CBS This Morning Segment about HSCT for RRMS, with Dr. Burt commenting on the treatments and results. There is a short but nice cost benefit ratio discussion about the cost of the treatment relative to MS drug costs.
Tag Archives: RRMS
JAMA Publishes HSCT for RRMS Results
It’s been a long time coming but it has finally happened!
The Journal of the American Medical Association (JAMA) has published Dr. Burt’s results from his Phase 3 Clinical Trial for HSCT ( Hematopoietic Stem Cell Transplant) treating RRMS (Relapse Remitting Multiple Sclerosis)!
https://jamanetwork.com/journals/jama/article-abstract/2720728
Thank you Dr. Burt for saving my life! I am so blessed to have been able to receive this treatment.
HSCT for Relapse Remitting Multiple Sclerosis – Phase 3 Clinical Trial
Here is the direct link from ClinicalTrials.gov to (MOST) – Maximizing Outcome of Multiple Sclerosis Transplantation.
This is the study, run by Dr. Richard Burt, that is currently recruiting people ages 18-58 with RRMS (Relapse Remitting Multiple Sclerosis) at Northwestern in Chicago, Illinois.
You will be able to see and read about all the criteria necessary to apply to the study as well as the protocol and contact information.
https://clinicaltrials.gov/ct2/show/study/NCT03342638
Study Description
Brief Summary:
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominantly an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. The investigators propose a randomized study of autologous unmanipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two different conditioning regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).